Evidence map›Paper›PMID 21991368›Full record

ArticlePloS one2011

Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis.

Rishi R Rampersad, Teresa K Tarrant, Christopher T Vallanat, Tatiana Quintero-Matthews, Michael F Weeks, Denise A Esserman, Jennifer Clark, Franco Di Padova, Dhavalkumar D Patel, Alan M Fong and 1 more

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Delivery of IL-35 byFrontiers in immunology · 2018
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. G protein signaling modulator-3: a leukocyte regulator of inflammation in health and disease.American journal of clinical and experimental immunology · 2014
    Review
  14. Article
  15. Article
  16. The role of the immune system in Huntington's disease.Clinical & developmental immunology · 2013
    Review
  17. Article
  18. Article
  19. Pathways for bone loss in inflammatory disease.Current osteoporosis reports · 2012
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rishi R RampersadDepartment of Medicine, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Teresa K Tarrant
Christopher T Vallanat
Tatiana Quintero-Matthews
Michael F Weeks
Denise A Esserman
Jennifer Clark
Franco Di Padova
Dhavalkumar D Patel
Alan M Fong
Peng Liu

Funding

Role of CX3CR1 in the Pathogenesis of AtherosclerosisR01HL077406 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FONG, ALAN M · 2006 to 2010
$1.8M
NHLBI NIH HHS HL077406NHLBI NIH HHS R01 HL077406
6 · The paper itself

Abstract

CCR2 is considered a proinflammatory mediator in many inflammatory diseases such as rheumatoid arthritis. However, mice lacking CCR2 develop exacerbated collagen-induced arthritis. To explore the underlying mechanism, we investigated whether autoimmune-associated Th17 cells were involved in the pathogenesis of the severe phenotype of autoimmune arthritis. We found that Th17 cells were expanded approximately 3-fold in the draining lymph nodes of immunized CCR2(-/-) mice compared to WT controls (p = 0.017), whereas the number of Th1 cells and regulatory T cells are similar between these two groups of mice. Consistently, levels of the Th17 cell cytokine IL-17A and Th17 cell-associated cytokines, IL-6 and IL-1β were approximately 2-6-fold elevated in the serum and 22-28-fold increased in the arthritic joints in CCR2(-/-) mice compared to WT mice (p = 0.04, 0.0004, and 0.01 for IL-17, IL-6, and IL-1β, respectively, in the serum and p = 0.009, 0.02, and 0.02 in the joints). Furthermore, type II collagen-specific antibodies were significantly increased, which was accompanied by B cell and neutrophil expansion in CCR2(-/-) mice. Finally, treatment with an anti-IL-17A antibody modestly reduced the disease severity in CCR2(-/-) mice. Therefore, we conclude that while we detect markedly enhanced Th17-cell responses in collagen-induced arthritis in CCR2-deficient mice and IL-17A blockade does have an ameliorating effect, factors additional to Th17 cells and IL-17A also contribute to the severe autoimmune arthritis seen in CCR2 deficiency. CCR2 may have a protective role in the pathogenesis of autoimmune arthritis. Our data that monocytes were missing from the spleen while remained abundant in the bone marrow and joints of immunized CCR2(-/-) mice suggest that there is a potential link between CCR2-expressing monocytes and Th17 cells during autoimmunity.

Indexed as

AnimalsAntibodiesArthritis, ExperimentalAutoantibodiesAutoimmune DiseasesB-LymphocytesBone MarrowCell ProliferationEpitopesImmunizationInterleukin-17JointsLymph NodesMiceMice, Inbred C57BLMice, Inbred DBAAntibodiesAutoantibodiesCcr2 protein, mouseEpitopesInterleukin-17Receptors, CCR2

Identifiers

PMID21991368
PMCPMC3186765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.